Melanoma vaccine - AVAX Technologies

Drug Profile

Melanoma vaccine - AVAX Technologies

Alternative Names: DNP-VACC; M-Vax; Melanoma vaccine DNP VACC; MVax

Latest Information Update: 21 Oct 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AVAX Technologies
  • Class Cancer vaccines; Conjugate-vaccines; Dinitrobenzenes; Haptens
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Malignant melanoma

Most Recent Events

  • 04 Aug 2015 Phase III development is ongoing in USA
  • 01 Dec 2011 Phase-III clinical trials in Malignant melanoma in USA (Intradermal)
  • 01 Dec 2011 Phase-III clinical trials in Malignant melanoma in Belgium (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top